Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
First subjects enrolled in pivotal Phase 3 study 158 men currently enrolled in 500 patient 6 month open label study Repros believes open label study provides encouraging data to support...
-
THE WOODLANDS, Texas, Sept. 4, 2012 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) announced today that it entered into a purchase agreement with several institutional investors to...
-
THE WOODLANDS, Texas, Aug. 27, 2012 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced the FDA has provided guidance for a Phase 2 study of low dose oral Proellex®...
-
THE WOODLANDS, Texas, Aug. 13, 2012 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the second quarter ended June 30, 2012. Liquidity and...
-
THE WOODLANDS, Texas, July 30, 2012 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced the FDA has scheduled a meeting to discuss the design of a Phase 2 endometriosis...
-
Consistent efficacy across all 3 endpoints after 4 months of treatment at 12mg vaginal dose Company anticipates full clinical results at or around year end End of Phase 2 meeting with...
-
Repros must submit protocol for FDA concurrence before initiation of the study Partial clinical hold on oral Proellex® to remain in place until this Phase 2 study is completed and...
-
THE WOODLANDS, Texas, July 9, 2012 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced it has reached agreement with the FDA for the design of the pivotal efficacy studies...
-
Company Believes Minutes Confirm FDA Requirements for NDA Pending Enrollment, Repros Believes NDA Can be Submitted 4Q 2013/1Q 2014 THE WOODLANDS, Texas, June 18, 2012 (GLOBE NEWSWIRE) --...
-
Company to Webcast Presentation on June 7, 2012 THE WOODLANDS, Texas, June 4, 2012 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that Joseph S. Podolski,...